Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04688632 · ClinicalTrials.gov registry record · Phase 1
Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects
A Phase 1 study, sponsored by Theravance Biopharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT04688632 is a Phase 1 study that has completed, run by Theravance Biopharma. The registered enrollment target is 72 participants.
The verdict
NCT04688632, a Phase 1 study, has completed, sponsored by Theravance Biopharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
A double-blind study to characterize the effect of ampreloxetine on cardiac repolarization in healthy subjects.
Interventions
- DRUG Moxifloxacin
- DRUG Moxifloxacin Placebo
- DRUG Ampreloxetine <Dose A>
- DRUG Ampreloxetine <Dose B>
- DRUG Ampreloxetine Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2021-01-18 |
| Est. Completion | 2021-03-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04688632
The ClinicalTrials.gov registry entry for NCT04688632 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theravance Biopharma, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Moxifloxacin is the first listed.
NCT04688632 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04688632 about?
NCT04688632 is a clinical study titled "Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects". A double-blind study to characterize the effect of ampreloxetine on cardiac repolarization in healthy subjects.
What is the current status of trial NCT04688632?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2021-01-18. Estimated completion is 2021-03-26.
What interventions are being tested in trial NCT04688632?
The interventions under investigation include: Moxifloxacin (DRUG), Moxifloxacin Placebo (DRUG), Ampreloxetine <Dose A> (DRUG), Ampreloxetine <Dose B> (DRUG), Ampreloxetine Placebo (DRUG).
Who is sponsoring clinical trial NCT04688632?
This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.